Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeremy Wright is active.

Publication


Featured researches published by Jeremy Wright.


Biosensors and Bioelectronics | 1997

Evaluation of a fiber optic immunosensor for quantitating cocaine in coca leaf extracts

Amr R. Toppozada; Jeremy Wright; Amira T. Eldefrawi; Mohyee E. Eldefrawi; Emanuel L. Johnson; Stephen D. Emche; Charles S. Helling

A fiber optic evanescent fluoroimmunosensor was used to rapidly detect and quantitate coca alkaloids as cocaine equivalents in leaf extracts of five Erythroxylum species. A monoclonal antibody (mAb) made against benzoylecgonine (BE), a major metabolite of cocaine, was immobilized covalently on quartz fibers and used as the biological sensing element in the portable fluorometer. Benzoylecgonine-fluorescein (BE-FL) was used as the optical signal generator when it bound to the fiber. If present, cocaine competed for the mAb and interfered with the binding of BE-FL, thereby reducing the fluorescence transmitted by the fiber. Calibration curves were prepared by measuring (over 30 s) the rates of fluorescence increase in the absence, or presence of cocaine. Ethanol or acid extracts of dry coca leaves were assayed by this fiber optic biosensor, gas chromatography and a fluorescent polarization immune assay. Biosensor values of cocaine content of leaves from five Erythroxylum species were not significantly different from gas chromatography values, but had higher variance. The biosensor assay was rapid and did not require cleanup of the crude leaf extracts. Cocaine in acid extracts was reduced significantly after 4 weeks at 23 degrees C and after 3 weeks at 37 degrees C. Fibers (mAb-coated), stored at 37 degrees C in phosphate-buffered solution (0.02% NaN3), gave stable responses for 14 days.


Xenobiotica | 1977

The Metabolism of Amphetamine in vitro by Rabbit Liver Preparations: A Comparison of R(−) and S(+) Enantiomers

Jeremy Wright; Arthur K. Cho; Joseph Gal

1. Incubation of R(-), S(+) and RS(+/-) amphetamines with rabbit liver 9000 g supernatant indicated that R(-) was metabolized at a faster rate than S(+), but that racemic amphetamine was metabolized at the same rate as S(+) during one hour incubations. 2. N-Hydroxyamphetamine and 1-phenyl-2-propranol were the major compounds detected in both R(-) and S(+) amphetamine incubations. 3. Phenylacetone oxime was detected in significant quantities after 3 h incubations of R(-) amphetamine, but only in minor quantities from S(+). 4. A fall in the amount of N-hydroxyamphetamine present in R(-) amphetamine incubations after a 3 h period as compared to a 1 h incubation, paralleled by a rise in the amount of phenylacetone oxime during 3 h suggested that the oxime was derived as a secondary metabolics from N-hydroxyamphetamine. 5. R(-) and S(+) N-hydroxyamphetamines were both metabolized to phenylacetone oxime by rabbit liver 9000 g supernatant, but the R(-) enantiomer was converted at a faster rate than S(+).


Journal of Analytical Toxicology | 1999

A rapid reusable fiber optic biosensor for detecting cocaine metabolites in urine.

Nidhi Nath; Mohyee E. Eldefrawi; Jeremy Wright; David Darwin; Marilyn A. Huestis

Analyte 2000, a four-channel fiber optic biosensor (FOB), was used for analysis of cocaine and its metabolites (COC) in human urine using a competitive fluorescence immunoassay. Binding of antibenzoylecgonine monoclonal antibody (mAb) to the casein-benzoylecgonine Ag-coated, tapered optical fibers was inhibited by COC. Bound mAb, which inversely correlated with COC concentration, was quantitated by fluorescence produced by evanescent excitation of bound cyanine dye-tagged antimouse antibody (CY5-Ab). The effective concentration range of benzoylecgonine (BE) for inhibiting the fluorescent signals was 0.75-50 ng/mL, with IC50 of 9.0 ng/mL. This FOB had similar affinities for BE, cocaine, and cocaethylene, but very low affinities for ecgonine and ecgonine methyl ester. A sensitivity of 100% and a specificity of 96% were achieved when 54 human urine specimens were analyzed by FOB (cutoff, 300 ng/mL COC) and GC-MS (cutoff, 150 ng/mL BE). All results were in agreement except for one positive FOB result with a GC-MS BE concentration of 148 ng/mL. In addition, regeneration and reuse of the fiber for multiple analyses were performed successfully with no carryover from specimens containing high COC concentrations to specimens containing low COC concentrations.


Journal of Immunological Methods | 1999

Assessment of an automated solid phase competitive fluoroimmunoassay for benzoylecgonine in untreated urine

Kevin P. O'Connell; James J. Valdes; Nehad Azer; Robert P. Schwartz; Jeremy Wright; Mohyee E. Eldefrawi

A new solid phase fluoroimmunoassay using a fully automated flow fluorometer adapted for urinalysis of drug metabolites is described. Fluorescein-conjugated benzoylecgonine (FL-BE) and monoclonal antibodies (mAb) against benzoylecgonine (BE) were the reagents used for demonstration. The solid phase consisted of anti-BE mAbs immobilized on the surface of polymethyl methacrylate (PMMA) beads. Free BE in solution competed with FL-BE and reduced bead-bound fluorescence in a concentration-dependent manner. The binding of FL-BE to the anti-BE mAb reached steady-state within minutes. FL-BE was not bound by uncoated beads nor beads coated with non-specific proteins or IgG. The signal-to-noise ratio was 33, and the sensitivity of the assay was 2 ng ml(-1) for BE. The effective concentration of BE was 1 to 100 ng ml(-1), with an IC50 value of 12 ng ml(-1). The mAb showed equal affinities for BE, cocaine, and cocaethylene, but a five order-of-magnitude lower affinity for ecgonine and ecgonine methylester. In a double-blind comparison using clinical urine samples, the data from this single-step competitive assay had excellent agreement with results obtained using a fiber-optic biosensor (FOB), and the EMIT assay performed commercially. The assay provided kinetic data rapidly and can be used to detect small analytes for which antibodies and fluorescein conjugates are available. The affinity of the mAb for FL-BE, calculated from kinetic analysis of the time course of the on and off reaction, was 2.25 x 10(-9) M.


Applied Biochemistry and Biotechnology | 2000

A sensitive solid-phase fluoroimmunoassay for detection of opiates in urine.

Mohyee E. Eldefrawi; Nehad Azer; Nidhi Nath; Nabil A. Anis; M. Bangalore; Kevin P. O'Connell; Robert P. Schwartz; Jeremy Wright

An automated flow fluorometer designed for kinetic binding analysis was adapted to develop a solid-phase competitive fluoroimmunoassay for urinalysis of opiates. The solid phase consisted of polymer beads coated with commercial monoclonal antibodies (MAbs) raised against morphine. Fluorescein-conjugated morphine (FL-MOR) was used as the fluorescein-labeled hapten. The dissociation equilibrium constant (KD) for the binding of FL-MOR to the anti-MOR MAb was 0.23 nM. The binding of FL-MOR to the anti-MOR MAb reached steady state within minutes and was displaced effectively by morphine and other opiates. Morphine-3-glucuronide (M3G), the major urinary metabolite of heroin and morphine, competed effectively with FL-MOR in a concentration-dependent manner for binding to the antimorphine MAb and was therefore used to construct the calibration curve. The sensitivity of the assay was 0.2 ng/mL for M3G. The assay was effective at concentrations of M3G from 0.2 to 50 ng/mL, with an IC50 of 2 ng/mL. Other opiates and heroin metabolites that showed >50% crossreactivity when present at 1 µg/mL included codeine, morphine-6-glucuronide, and oxycodone. Methadone showed very low crossreactivity (<5%), which is a benefit for testing in patients being treated for opiate addictions. The high sensitivity of the assay and the relatively high cutoff value for positive opiate tests allows very small sample volumes (e.g., in saliva or sweat) to be analyzed. A double-blind comparison using 205 clinical urine samples showed good agreement between this single-step competitive assay and a commercially performed enzyme multiplied immunoassay technique for the detection of opiates and benzoylecgonine (a metabolite of cocaine).


Biochemical Pharmacology | 1972

Biogenic amine-depleting effects of benzimidazole-5(6)-dl-alanine☆

Eugene M. Johnson; Nicolas Zenker; Jeremy Wright

Abstract Studies in vivo on benzimidazole-5(6)- dl -alanine were carried out by administering the compound in aqueous solutions intraperitoneally to male Wistar rats. Benzimidazole alanine (278 mg/kg) decreased heart norepinephrine (80 per cent), brain norepinephrine (58 per cent) and brain dopamine (70 per cent) within 3 hr and brain serotonin (70 per cent) within 1 hr of administration. Benzimidazole ethylamine (100 mg/kg) produced a 60 per cent decrease in heart norepinephrine within 3 hr of administration and benzimidazole alanine was not able to reduce heart norepinephrine in animals pretreated with the decarboxylase inhibitor, dl -seryl-2,3,4-trihydroxybenzylhydrazine hydrochloride (Ro-4-4602 before benzimidazole alanine administration). Benzimidazole alanine, administered prior to tranylcypromine completely blocked the increase in brain norepinephrine and dopamine after monoamine oxidase inhibition and reduced the increase in brain serotonin by 65 per cent.


Pharmaceutical Research | 1989

A Nuclear Magnetic Resonance (NMR) Method for the Determination of the cis/trans Isomeric Content of Chlorprothixene

Karl-Heinz A. Rosler; Jeremy Wright; Kristine M. Fox; Rolland M. Waters; Patrick S. Callery

Proton NMR spectroscopy was applied to the assignment of the isomeric identity of commercially available chlorprothixene. Nuclear Overhauser effect studies confirmed that the clinically useful isomer is the cis (Z) configuration. An NMR method for determining the isomeric content of chlorprothixene was developed based on integration of the ratio of areas of signal strength of the cis-N-methyl in comparison to the trans-N-methyl resonances.


Biochemical Pharmacology | 1976

Effects of DL-3-(5-benzimidazolyl)-2methylalanine on brain and heart catecholamines—I. Depleting effects

Nicolas Zenker; V.H. Morgenroth; Jeremy Wright; J.W. King; Carroll Dwight Arnett

Abstract The intraperitoneal administration of DL -3-(5-benzimidazolyl)-2-methylalanine (MBA) causes a marked decline in rat brain and heart catecholamines. The release of tritiated norepinephrine from the rat heart by MBA indicates a release component in the action of the compound. The releasing potency of decarboxylated MBA and the inability of MBA to lower heart norepinephrine in the presence of a decarboxylase inhibitor implicate a decarboxylation product of the amino acid as responsible for the release of norepinephrine by MBA. When MBA and then a monoamine oxidase inhibitor are administered to reserpinized rats, the level of brain amines remains constant, indicating inhibition of norepinephrine synthesis in vivo . The activity of tissue tyrosine hydroxylase in MBA-treated rats confirms this inhibition.


Journal of Medicinal Chemistry | 1998

(−)-3β-Substituted Ecgonine Methyl Esters as Inhibitors for Cocaine Binding and Dopamine Uptake

Spencer F. Lieske; Biao Yang; Mohyee E. Eldefrawi; and Alexander D. MacKerell; Jeremy Wright


Journal of Agricultural and Food Chemistry | 1995

Fiber optic immunosensor for polychlorinated biphenyls

Christopher Q. Zhao; Nabil A. Anis; Kim R. Rogers; Richard H. Kline; Jeremy Wright; Amira T. Eldefrawi; Mohyee E. Eldefrawi

Collaboration


Dive into the Jeremy Wright's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard H. Kline

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Eshleman Aj

University of Maryland

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge